A molecular and chemical perspective in defining melatonin receptor subtype selectivity

International Journal of Molecular Sciences

Volumn 14, Issue 9, 2013, Pages 18385-18406

  Chan, King Hang ^a   Wong, Yung Hou ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

GPCR; Melatonin; MT1; MT2; Subtype selectivity

Indexed keywords

2 IODOMELATONIN; 2 PHENYLMELATONIN; 5 METHOXYLUZINDOLE; ADENYLATE CYCLASE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AGOMELATINE; BETA METHYL 6 CHLOROMELATONIN; DH 97; GUANINE NUCLEOTIDE BINDING PROTEIN; IIK 7; ISOQUINOLONE DERIVATIVE; K 185; LUZINDOLE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONINERGIC AGENT; MOLECULAR SCAFFOLD; N 0889; PHENYLPROPYLAMIDE DERIVATIVE; PHOSPHOLIPASE C; S 24014; S 24773; S 28407; SEROTONIN 2C RECEPTOR; TASIMELTEON; UCM 765; UCM 924; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANTIOXIDANT ACTIVITY; BINDING AFFINITY; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CHRONOBIOLOGY; CIRCADIAN RHYTHM; DRUG DESIGN; DRUG DEVELOPMENT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENDOCRINE REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; HOMOLOGY MODELING; HORMONE SYNTHESIS; HUMAN; IMMUNOMODULATION; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PINEAL BODY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REPRODUCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MELATONIN; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTORS, MELATONIN; SIGNAL TRANSDUCTION;

EID: 84883689093     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140918385     Document Type: Review

References (111)

1. Poeggeler, B.; Reiter, R.J.; Tan, D.X.; Chen, L.D.; Manchester, L.C. Melatonin, hydroxyl radical-mediated oxidative damage, and aging: A hypothesis. J. Pineal Res. 1993, 14, 151-168.
2. Kennaway, D.; Wright, H. Melatonin and circadian rhythms. Curr. Top. Med. Chem. 2002, 2, 199-209.
3. Geoffriau, M.; Claustrat, B.; Veldhuis, J. Estimation of frequently sampled nocturnal melatonin production in humans by deconvolution analysis: Evidence for episodic or ultradian secretion. J. Pineal Res. 1999, 27, 139-144.
4. Pandi-Perumal, S.; Srinivasan, V.; Maestroni, G.; Cardinali, D.; Poeggeler, B.; Hardeland, R. Melatonin: Nature's most versatile biological signal? FEBS J. 2006, 273, 2813-2838.
5. Cardinali, D.; Furio, A.; Reyes, M.; Brusco, L. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control. 2006, 17, 601-609.
6. Dawson, D.; Armstrong, S. Chronobiotics-Drugs that shift rhythms. Pharmacol. Ther. 1996, 69, 15-36.
7. Arendt, J.; Skene, D. Melatonin as a chronobiotic. Sleep Med. Rev. 2005, 9, 25-39.
8. Touitou, Y.; Bogdan, A. Promoting adjustment of the sleep-wake cycle by chronobiotics. Physiol. Behav. 2007, 90, 294-300.
9. Sack, R.L.; Auckley, D.; Auger, R.R.; Carskadon, M.A.; Wright, K.P.; Vitiello, M.V.; Zhdanova, I.V.; Medicine, A.A.O.S. Circadian rhythm sleep disorders: part I, basic principles, shift work and jet lag disorders. An American Academy of Sleep Medicine review. Sleep 2007, 30, 1460-1483.
10. Kayumov, L.; Brown, G.; Jindal, R.; Buttoo, K.; Shapiro, C.M. A randomized, double-blind, placebo-controlled crossover study of the effect of exogenous melatonin on delayed sleep phase syndrome. Psychosom. Med. 2001, 63, 40-48.
11. Sack, R.L.; Auckley, D.; Auger, R.R.; Carskadon, M.A.; Wright, K.P.; Vitiello, M.V.; Zhdanova, I.V.; Medicine, A.A.O.S. Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review. Sleep 2007, 30, 1484-1501.
12. Skene, D.J.; Arendt, J. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med. 2007, 8, 651-655.
13. Herxheimer, A.; Petrie, K.J. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst. Rev. 2002, doi:10.1002/14651858.CD001520.
14. Arendt, J. Melatonin and human rhythms. Chronobiol. Int. 2006, 23, 21-37.
15. Ekmekcioglu, C. Melatonin receptors in humans: biological role and clinical relevance. Biomed. Pharmacother. 2006, 60, 97-108.
16. Ram, P.; Dai, J.; Yuan, L.; Dong, C.; Kiefer, T.; Lai, L.; Hill, S. Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 2002, 179, 141-150.
17. Carrillo-Vico, A.; Reiter, R.; Lardone, P.; Herrera, J.; Fernández-Montesinos, R.; Guerrero, J.; Pozo, D. The modulatory role of melatonin on immune responsiveness. Curr. Opin. Investig. Drugs 2006, 7, 423-431.
18. Bondy, S.C.; Sharman, E.H. Melatonin and the aging brain. Neurochem. Int. 2007, 50, 571-580.
19. De Jonghe, A.; Korevaar, J.C.; van Munster, B.C.; de Rooij, S.E. Effectiveness of melatonin treatment on circadian rhythm disturbances in dementia. Are there implications for delirium? A systematic review. Int. J. Geriatr. Psychiatry 2010, 25, 1201-1208.
20. Jan, J.E.; Reiter, R.J.; Wong, P.K.; Bax, M.C.; Ribary, U.; Wasdell, M.B. Melatonin has membrane receptor-independent hypnotic action on neurons: An hypothesis. J. Pineal Res. 2011, 50, 233-240.
21. Larson, E.B.; Zollman, F.S. The effect of sleep medications on cognitive recovery from traumatic brain injury. J. Head Trauma Rehabil. 2010, 25, 61-67.
22. Reiter, R.J.; Tan, D.X.; Manchester, L.C.; Tamura, H. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J. Physiol. Pharmacol. 2007, 58, 5-22.
23. Ebisawa, T.; Karne, S.; Lerner, M.; Reppert, S. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc. Natl. Acad. Sci. USA 1994, 91, 6133-6137.
24. Reppert, S.; Godson, C.; Mahle, C.; Weaver, D.; Slaugenhaupt, S.; Gusella, J. Molecular characterization of a second melatonin receptor expressed in human retina and brain: The Mel1b melatonin receptor. Proc. Natl. Acad. Sci. USA 1995, 92, 8734-8738.
25. Reppert, S.; Weaver, D.; Ebisawa, T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994, 13, 1177-1185.
26. Dubocovich, M.; Markowska, M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine 2005, 27, 101-110.
27. Slaugenhaupt, S.; Roca, A.; Liebert, C.; Altherr, M.; Gusella, J.; Reppert, S. Mapping of the gene for the Mel1a-melatonin receptor to human chromosome 4 (MTNR1A) and mouse chromosome 8 (Mtnr1a). Genomics 1995, 27, 355-357.
28. Reppert, S.; Weaver, D.; Ebisawa, T.; Mahle, C.; Kolakowski, L.J. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett. 1996, 386, 219-224.
29. Levoye, A.; Dam, J.; Ayoub, M.; Guillaume, J.; Couturier, C.; Delagrange, P.; Jockers, R. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 2006, 25, 3012-3023.
30. Becker-André, M.; Wiesenberg, I.; Schaeren-Wiemers, N.; André, E.; Missbach, M.; Saurat, J.; Carlberg, C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J. Biol. Chem. 1994, 269, 28531-28534.
31. Skwarlo-Sonta, K.; Majewski, P.; Markowska, M.; Oblap, R.; Olszanska, B. Bidirectional communication between the pineal gland and the immune system. Can. J. Physiol. Pharmacol. 2003, 81, 342-349.
32. Pandi-Perumal, S.; Trakht, I.; Srinivasan, V.; Spence, D.; Maestroni, G.; Zisapel, N.; Cardinali, D. Physiological effects of melatonin: Role of melatonin receptors and signal transduction pathways. Prog. Neurobiol. 2008, 85, 335-353.
33. Liu, C.; Weaver, D.; Jin, X.; Shearman, L.; Pieschl, R.; Gribkoff, V.; Reppert, S. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997, 19, 91-102.
34. Reiter, R. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr. Rev. 1991, 12, 151-180.
35. Dubocovich, M.; Rivera-Bermudez, M.; Gerdin, M.; Masana, M. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci. 2003, 8, d1093-d1108.
36. Clemens, J.; Jarzynka, M.; Witt-Enderby, P. Down-regulation of mt1 melatonin receptors in rat ovary following estrogen exposure. Life Sci. 2001, 69, 27-35.
37. Frungieri, M.; Mayerhofer, A.; Zitta, K.; Pignataro, O.; Calandra, R.; Gonzalez-Calvar, S. Direct effect of melatonin on Syrian hamster testes: Melatonin subtype 1a receptors, inhibition of androgen production, and interaction with the local corticotropin-releasing hormone system. Endocrinology 2005, 146, 1541-1552.
38. Masana, M.; Doolen, S.; Ersahin, C.; Al-Ghoul, W.; Duckles, S.; Dubocovich, M.; Krause, D. MT(2) melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther. 2002, 302, 1295-1302.
39. Naji, L.; Carrillo-Vico, A.; Guerrero, J.; Calvo, J. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci. 2004, 74, 2227-2236.
40. Zalatan, F.; Krause, J.; Blask, D. Inhibition of isoproterenol-induced lipolysis in rat inguinal adipocytes in vitro by physiological melatonin via a receptor-mediated mechanism. Endocrinology 2001, 142, 3783-3790.
41. Guerrero, J.; Reiter, R. Melatonin-immune system relationships. Curr. Top. Med. Chem. 2002, 2, 167-179.
42. Brydon, L.; Roka, F.; Petit, L.; de Coppet, P.; Tissot, M.; Barrett, P.; Morgan, P.; Nanoff, C.; Strosberg, A.; Jockers, R. Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol. Endocrinol. 1999, 13, 2025-2038.
43. Masana, M.I.; Dubocovich, M.L. Melatonin receptor signaling: finding the path through the dark. Sci. STKE 2001, 2001, doi:10.1126/scisignal.1072001pe39.
44. Travnickova-Bendova, Z.; Cermakian, N.; Reppert, S.M.; Sassone-Corsi, P. Bimodal regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/BMAL1 activity. Proc. Natl. Acad. Sci. USA 2002, 99, 7728-7733.
45. Jin, X.; von Gall, C.; Pieschl, R.; Gribkoff, V.; Stehle, J.; Reppert, S.; Weaver, D. Targeted disruption of the mouse Mel(1b) melatonin receptor. Mol. Cell. Biol. 2003, 23, 1054-1060.
46. Chan, A.; Lai, F.; Lo, R.; Voyno-Yasenetskaya, T.; Stanbridge, E.; Wong, Y. Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins. Cell Signal. 2002, 14, 249-257.
47. Kyriakis, J.M.; Banerjee, P.; Nikolakaki, E.; Dai, T.; Rubie, E.A.; Ahmad, M.F.; Avruch, J.; Woodgett, J.R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994, 369, 156-160.
48. van Dam, H.; Duyndam, M.; Rottier, R.; Bosch, A.; de Vries-Smits, L.; Herrlich, P.; Zantema, A.; Angel, P.; van der Eb, A.J. Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J. 1993, 12, 479-487.
49. Zinck, R.; Cahill, M.A.; Kracht, M.; Sachsenmaier, C.; Hipskind, R.A.; Nordheim, A. Protein synthesis inhibitors reveal differential regulation of mitogen-activated protein kinase and stress-activated protein kinase pathways that converge on Elk-1. Mol. Cell. Biol. 1995, 15, 4930-4938.
50. Garcia-Mauriño, S.; Gonzalez-Haba, M.G.; Calvo, J.R.; Rafii-El-Idrissi, M.; Sanchez-Margalet, V.; Goberna, R.; Guerrero, J.M. Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: A possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 1997, 159, 574-581.
51. Lau, W.W.; Ng, J.K.; Lee, M.M.; Chan, A.S.; Wong, Y.H. Interleukin-6 autocrine signaling mediates melatonin MT(1/2) receptor-induced STAT3 Tyr(705) phosphorylation. J. Pineal Res. 2012, 52, 477-489.
52. Eddahri, F.; Denanglaire, S.; Bureau, F.; Spolski, R.; Leonard, W.J.; Leo, O.; Andris, F. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood 2009, 113, 2426-2433.
53. Shen, L.; Fahey, J.V.; Hussey, S.B.; Asin, S.N.; Wira, C.R.; Fanger, M.W. Synergy between IL-8 and GM-CSF in reproductive tract epithelial cell secretions promotes enhanced neutrophil chemotaxis. Cell. Immunol. 2004, 230, 23-32.
54. Drazen, D.; Nelson, R. Melatonin receptor subtype MT2 (Mel 1b) and not mt1 (Mel 1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 2001, 74, 178-184.
55. Drazen, D.; Bilu, D.; Bilbo, S.; Nelson, R. Melatonin enhancement of splenocyte proliferation is attenuated by luzindole, a melatonin receptor antagonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 280, R1476-R1482.
56. Weil, Z.; Hotchkiss, A.; Gatien, M.; Pieke-Dahl, S.; Nelson, R. Melatonin receptor (MT1) knockout mice display depression-like behaviors and deficits in sensorimotor gating. Brain Res. Bull. 2006, 68, 425-429.
57. Larson, J.; Jessen, R.; Uz, T.; Arslan, A.; Kurtuncu, M.; Imbesi, M.; Manev, H. Impaired hippocampal long-term potentiation in melatonin MT2 receptor-deficient mice. Neurosci. Lett. 2006, 393, 23-26.
58. Von Gall, C.; Weaver, D.; Moek, J.; Jilg, A.; Stehle, J.; Korf, H. Melatonin plays a crucial role in the regulation of rhythmic clock gene expression in the mouse pars tuberalis. Ann. N Y Acad. Sci. 2005, 1040, 508-511.
59. Dubocovich, M.; Hudson, R.; Sumaya, I.; Masana, M.; Manna, E. Effect of MT1 melatonin receptor deletion on melatonin-mediated phase shift of circadian rhythms in the C57BL/6 mouse. J. Pineal Res. 2005, 39, 113-120.
60. Gerdin, M.; Masana, M.; Rivera-Bermúdez, M.; Hudson, R.; Earnest, D.; Gillette, M.; Dubocovich, M. Melatonin desensitizes endogenous MT2 melatonin receptors in the rat suprachiasmatic nucleus: Relevance for defining the periods of sensitivity of the mammalian circadian clock to melatonin. FASEB J. 2004, 18, 1646-1656.
61. Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Imai, Y.; Hinuma, S.; Kato, K.; Nishikawa, H.; Hirai, K.; et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J. Med. Chem. 2002, 45, 4222-4239.
62. Dubocovich, M.; Takahashi, J. Use of 2-[125I]iodomelatonin to characterize melatonin binding sites in chicken retina. Proc. Natl. Acad. Sci. USA 1987, 84, 3916-3920.
63. Nonno, R.; Lucini, V.; Pannacci, M.; Mazzucchelli, C.; Angeloni, D.; Fraschini, F.; Stankov, B. Pharmacological characterization of the human melatonin Mel1a receptor following stable transfection into NIH3T3 cells. Br. J. Pharmacol. 1998, 124, 485-492.
64. Mulchahey, J.; Goldwater, D.; Zemlan, F. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog beta-methyl-6-chloromelatonin. Life Sci. 2004, 75, 1843-1856.
65. Hardeland, R. Investigational melatonin receptor agonists. Expert Opin. Investig. Drugs 2010, 19, 747-764.
66. Zlotos, D.P. Recent advances in melatonin receptor ligands. Arch. Pharm. (Weinheim) 2005, 338, 229-247.
67. Mor, M.; Rivara, S.; Pala, D.; Bedini, A.; Spadoni, G.; Tarzia, G. Recent advances in the development of melatonin MT(1) and MT(2) receptor agonists. Expert Opin. Ther. Pat. 2010, 20, 1059-1077.
68. Zlotos, D.P. Recent progress in the development of agonists and antagonists for melatonin receptors. Curr. Med. Chem. 2012, 19, 3532-3549.
69. Kato, K.; Hirai, K.; Nishiyama, K.; Uchikawa, O.; Fukatsu, K.; Ohkawa, S.; Kawamata, Y.; Hinuma, S.; Miyamoto, M. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005, 48, 301-310.
70. Bourin, M.; Mocaër, E.; Porsolt, R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J. Psychiatry Neurosci. 2004, 29, 126-133.
71. Millan, M.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman-Tancredi, A.; Pasteau, V.; Rivet, J.; Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003, 306, 954-964.
72. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.; et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn. Schmiedeberg Arch. Pharmacol. 2003, 367, 553-561.
73. Ettaoussi, M.; Sabaouni, A.; Rami, M.; Boutin, J.A.; Delagrange, P.; Renard, P.; Spedding, M.; Caignard, D.H.; Berthelot, P.; Yous, S. Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I). Eur. J. Med. Chem. 2012, 49, 310-323.
74. Hardeland, R. Tasimelteon, a melatonin agonist for the treatment of insomnia and circadian rhythm sleep disorders. Curr. Opin. Investig. Drugs 2009, 10, 691-701.
75. Dubocovich, M.; Masana, M.; Iacob, S.; Sauri, D. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn. Schmiedeberg Arch. Pharmacol. 1997, 355, 365-375.
76. Teh, M.; Sugden, D. Comparison of the structure-activity relationships of melatonin receptor agonists and antagonists: Lengthening the N-acyl side-chain has differing effects on potency on Xenopus melanophores. Naunyn. Schmiedeberg Arch. Pharmacol. 1998, 358, 522-528.
77. Faust, R.; Garratt, P.J.; Jones, R.; Yeh, L.K.; Tsotinis, A.; Panoussopoulou, M.; Calogeropoulou, T.; Teh, M.T.; Sugden, D. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J. Med. Chem. 2000, 43, 1050-1061.
78. Wallez, V.; Durieux-Poissonnier, S.; Chavatte, P.; Boutin, J.; Audinot, V.; Nicolas, J.; Bennejean, C.; Delagrange, P.; Renard, P.; Lesieur, D. Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands. J. Med. Chem. 2002, 45, 2788-2800.
79. Descamps-François, C.; Yous, S.; Chavatte, P.; Audinot, V.; Bonnaud, A.; Boutin, J.; Delagrange, P.; Bennejean, C.; Renard, P.; Lesieur, D. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J. Med. Chem. 2003, 46, 1127-1129.
80. Rivara, S.; Mor, M.; Bedini, A.; Spadoni, G.; Tarzia, G. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr. Top. Med. Chem. 2008, 8, 954-968.
81. Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Scaglione, F.; Sanchez, R.O.; et al. N-(substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J. Med. Chem. 2007, 50, 6618-6626.
82. Rivara, S.; Pala, D.; Lodola, A.; Mor, M.; Lucini, V.; Dugnani, S.; Scaglione, F.; Bedini, A.; Lucarini, S.; Tarzia, G.; et al. MT(1)-Selective Melatonin Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Dynamics Investigation of N-{[(3-O-Substituted) anilino]alkyl}amides. ChemMedChem 2012, 7, 1954-1964.
83. Sugden, D.; Pickering, H.; Teh, M.T.; Garratt, P.J. Melatonin receptor pharmacology: toward subtype specificity. Biol. Cell 1997, 89, 531-537.
84. Navajas, C.; Kokkola, T.; Poso, A.; Honka, N.; Gynther, J.; Laitinen, J.T. A rhodopsin-based model for melatonin recognition at its G protein-coupled receptor. Eur. J. Pharmacol. 1996, 304, 173-183.
85. Garratt, P.; Travard, S.; Vonhoff, S.; Tsotinis, A.; Sugden, D. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J. Med. Chem. 1996, 39, 1797-1805.
86. Spadoni, G.; Mor, M.; Tarzia, G. Structure-affinity relationships of indole-based melatonin analogs. Biol. Signals Recept. 1999, 8, 15-23.
87. Mor, M.; Rivara, S.; Silva, C.; Bordi, F.; Plazzi, P.V.; Spadoni, G.; Diamantini, G.; Balsamini, C.; Tarzia, G.; Fraschini, F.; et al. Melatonin receptor ligands: synthesis of new melatonin derivatives and comprehensive comparative molecular field analysis (CoMFA) study. J. Med. Chem. 1998, 41, 3831-3844.
88. Sugden, D.; Chong, N.; Lewis, D. Structural requirements at the melatonin receptor. Br. J. Pharmacol. 1995, 114, 618-623.
89. Spadoni, G.; Stankov, B.; Duranti, A.; Biella, G.; Lucini, V.; Salvatori, A.; Fraschini, F. 2-Substituted 5-methoxy-N-acyltryptamines: synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J. Med. Chem. 1993, 36, 4069-4074.
90. Beresford, I.; Browning, C.; Starkey, S.; Brown, J.; Foord, S.; Coughlan, J.; North, P.; Dubocovich, M.; Hagan, R. GR196429: A nonindolic agonist at high-affinity melatonin receptors. J. Pharmacol. Exp. Ther. 1998, 285, 1239-1245.
91. Mody, S.; Hu, Y.; Ho, M.; Wong, Y. In search of novel and therapeutically significant melatoninergic ligands. Recent Pat. CNS Drug Discov. 2007, 2, 241-245.
92. Hu, Y.; Ho, M.; Chan, K.; New, D.; Wong, Y. Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. Bioorg. Med. Chem. Lett. 2010, 20, 2582-2585.
93. Chan, K.H.; Hu, Y.; Ho, M.K.; Wong, Y.H. Characterization of Substituted Phenylpropylamides as Highly Selective Agonists at the Melatonin MT(2) Receptor. Curr. Med. Chem. 2013, 20, 289-300.
94. Gerdin, M.; Mseeh, F.; Dubocovich, M. Mutagenesis studies of the human MT2 melatonin receptor. Biochem. Pharmacol. 2003, 66, 315-320.
95. Kokkola, T.; Watson, M.A.; White, J.; Dowell, S.; Foord, S.M.; Laitinen, J.T. Mutagenesis of human Mel1a melatonin receptor expressed in yeast reveals domains important for receptor function. Biochem. Biophys. Res. Commun. 1998, 249, 531-536.
96. Conway, S.; Mowat, E.; Drew, J.; Barrett, P.; Delagrange, P.; Morgan, P. Serine residues 110 and 114 are required for agonist binding but not antagonist binding to the melatonin MT(1) receptor. Biochem. Biophys. Res. Commun. 2001, 282, 1229-1236.
97. Mazna, P.; Obsilova, V.; Jelinkova, I.; Balik, A.; Berka, K.; Sovova, Z.; Ettrich, R.; Svoboda, P.; Obsil, T.; Teisinger, J. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding. J. Neurochem. 2004, 91, 836-842.
98. Mazna, P.; Berka, K.; Jelinkova, I.; Balik, A.; Svoboda, P.; Obsilova, V.; Obsil, T.; Teisinger, J. Ligand binding to the human MT2 melatonin receptor: the role of residues in transmembrane domains 3, 6, and 7. BioChem. Biophys Res. Commun. 2005, 332, 726-734.
99. Farce, A.; Chugunov, A.O.; Logé, C.; Sabaouni, A.; Yous, S.; Dilly, S.; Renault, N.; Vergoten, G.; Efremov, R.G.; Lesieur, D.; et al. Homology modeling of MT1 and MT2 receptors. Eur. J. Med. Chem. 2008, 43, 1926-1944.
100. Mor, M.; Spadoni, G.; Di Giacomo, B.; Diamantini, G.; Bedini, A.; Tarzia, G.; Plazzi, P.V.; Rivara, S.; Nonno, R.; Lucini, V.; et al. Synthesis, pharmacological characterization and QSAR studies on 2-substituted indole melatonin receptor ligands. Bioorg. Med. Chem. 2001, 9, 1045-1057.
101. Rivara, S.; Lorenzi, S.; Mor, M.; Plazzi, P.V.; Spadoni, G.; Bedini, A.; Tarzia, G. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J. Med. Chem. 2005, 48, 4049-4060.
102. Shi, L.; Javitch, J.A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
103. Kristiansen, K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 2004, 103, 21-80.
104. Shi, L.; Liapakis, G.; Xu, R.; Guarnieri, F.; Ballesteros, J.A.; Javitch, J.A. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 2002, 277, 40989-40996.
105. Gloriam, D.E.; Foord, S.M.; Blaney, F.E.; Garland, S.L. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. J. Med. Chem. 2009, 52, 4429-4442.
106. Dubocovich, M.; Delagrange, P.; Krause, D.; Sugden, D.; Cardinali, D.; Olcese, J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, Classification, and Pharmacology of G Protein-Coupled Melatonin Receptors. Pharmacol. Rev. 2010, 62, 343-380.
107. Renault, N.; Gohier, A.; Chavatte, P.; Farce, A. Novel structural insights for drug design of selective 5-HT(2C) inverse agonists from a ligand-biased receptor model. Eur. J. Med. Chem. 2010, 45, 5086-5099.
108. Farce, A.; Dilly, S.; Yous, S.; Berthelot, P.; Chavatte, P. Homology modelling of the serotoninergic 5-HT2c receptor. J. Enzyme Inhib. Med. Chem. 2006, 21, 285-292.
109. Pala, D.; Beuming, T.; Sherman, W.; Lodola, A.; Rivara, S.; Mor, M. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J. Chem. Inf. Model. 2013, 53, 821-835.
110. Kufareva, I.; Rueda, M.; Katritch, V.; Stevens, R.C.; Abagyan, R.; participants, G.D. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure 2011, 19, 1108-1126.
111. Cherezov, V.; Rosenbaum, D.; Hanson, M.; Rasmussen, S.; Thian, F.; Kobilka, T.; Choi, H.; Kuhn, P.; Weis, W.; Kobilka, B.; et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318, 1258-1265.